Strategic Timing of AntiRetroviral Treatment (START)

Project no.: HIV-NAT 097 (NCT00867048)

A Multicenter Study of the International Network for Strategic Initiatives in Global HIV Trials

The purpose of this randomized study is to determine whether immediate initiation of antiretroviral treatment (ART) is superior to deferral of ART until the CD4+ declines below 350 cells/mm3 in terms of morbidity and mortality in HIV-1 infected persons who are antiretroviral naive with a CD4+ count above 500 cells/mm3. This is a landmark study to support early ART treatment for many international guideline including WHO guideline

Publications:

  1. START; design considerations for a large simple trial to examine the time to commence antiretroviral therapy for the treatment of HIV infection. J Clin Trials 2011. In press.
  2. Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study. Clin Trials 2012; 0:1-32.
  3. HIV antiretroviral therapy reduces circulating surfactant protein-D levels. HIV Med. 2011;12(9):580-1.
  4. HIV Med. 2015 Apr;16 Suppl 1:137-46.
  5. HIV Med. 2015 Apr;16 Suppl 1:1-9. 
  6. HIV Med. 2015 Apr;16 Suppl 1:129-36.
  7. HIV Med. 2015 Apr;16 Suppl S1:119-128.
  8. HIV Med. 2015 Apr;16 Suppl 1:109-18.
  9. HIV Med. 2015 Apr;16 Suppl S1:97-108.
  10. HIV Med. 2015 Apr;16 Suppl 1:88-96.
  11. HIV Med. 2015 Apr;16 Suppl 1:77-87.
  12. HIV Med. 2015 Apr;16 Suppl S1:64-76.
  13. HIV Med. 2015 Apr;16 Suppl 1:55-63.
  14. HIV Med. 2015 Apr;16 Suppl S1:46-54.
  15. HIV Med. 2015 Apr;16 Suppl 1:37-45.
  16. HIV Med. 2015 Apr;16 Suppl 1:30-6.
  17. HIV Med. 2015 Apr;16 Suppl 1:24-9.
  18. HIV Med. 2015 Apr;16 Suppl 1:14-23.